Condition
Astrocytoma, IDH-Mutant, Grade 3
Total Trials
4
Recruiting
1
Active
2
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
Termination Rate
0.0%
0 terminated out of 4 trials
Late-Stage Pipeline
50%
2 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
4Total
P 1 (2)
P 3 (2)
Trial Status
Not Yet Recruiting2
Active Not Recruiting1
Recruiting1
Clinical Trials (4)
Showing 4 of 4 trials
NCT07468136Phase 1Not Yet Recruiting
Retifanlimab With or Without Difluoromethylornithine for the Treatment of Progressive High Grade Gliomas
NCT03528642Phase 1Active Not Recruiting
Telaglenastat With Radiation Therapy and Temozolomide in Treating Patients With IDH-Mutated Diffuse Astrocytoma or Anaplastic Astrocytoma
NCT05303519Phase 3Recruiting
SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
NCT07215910Phase 3Not Yet RecruitingPrimary
Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer
Showing all 4 trials